These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 17272793)

  • 1. The physiology of incretin hormones and the basis for DPP-4 inhibitors.
    McKennon SA; Campbell RK
    Diabetes Educ; 2007; 33(1):55-6, 60-2, 65-6. PubMed ID: 17272793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Drucker DJ; Nauck MA
    Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes.
    Mest HJ; Mentlein R
    Diabetologia; 2005 Apr; 48(4):616-20. PubMed ID: 15770466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
    Green BD; Flatt PR; Bailey CJ
    Diab Vasc Dis Res; 2006 Dec; 3(3):159-65. PubMed ID: 17160910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
    Campbell RK
    Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gliptins.
    Focosi D; Kast RE; Petrini M
    Lancet; 2007 Jan; 369(9558):269-70. PubMed ID: 17258656
    [No Abstract]   [Full Text] [Related]  

  • 7. Gliptins.
    Grouzmann E; Buclin T; Biollaz J
    Lancet; 2007 Jan; 369(9558):269. PubMed ID: 17258657
    [No Abstract]   [Full Text] [Related]  

  • 8. Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.
    Gallwitz B
    Drugs Today (Barc); 2007 Jan; 43(1):13-25. PubMed ID: 17315049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors.
    Holst JJ; Deacon CF
    Diabetologia; 2005 Apr; 48(4):612-5. PubMed ID: 15759106
    [No Abstract]   [Full Text] [Related]  

  • 10. The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1.
    Nauck MA; El-Ouaghlidi A
    Diabetologia; 2005 Apr; 48(4):608-11. PubMed ID: 15761719
    [No Abstract]   [Full Text] [Related]  

  • 11. DPP-4 inhibitors and their potential role in the management of type 2 diabetes.
    Barnett A
    Int J Clin Pract; 2006 Nov; 60(11):1454-70. PubMed ID: 17073841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
    Langley AK; Suffoletta TJ; Jennings HR
    Pharmacotherapy; 2007 Aug; 27(8):1163-80. PubMed ID: 17655515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut hormones and related concepts.
    Bloomgarden ZT
    Diabetes Care; 2006 Oct; 29(10):2319-24. PubMed ID: 17003315
    [No Abstract]   [Full Text] [Related]  

  • 14. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus.
    Triplitt C; Wright A; Chiquette E
    Pharmacotherapy; 2006 Mar; 26(3):360-74. PubMed ID: 16503716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
    Gallwitz B
    Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What are incretins, and how will they influence the management of type 2 diabetes?
    Blonde L; Rosenstock J; Triplitt C
    J Manag Care Pharm; 2006 Sep; 12(7 Suppl A):S2-12; quiz S14-6. PubMed ID: 16981805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
    Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
    Siddiqui NI
    Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.